

For personal use only



Ovarian Cancer



ARL Pathology 568 St Kilda Road, Melbourne VIC 3004, Australia
T: +61 3 9529 2922 F:+61 3 9529 7277 E: info@arlaus.com.au W: www.arlaus.com.au

OvPlex™ is licensed from HealthLinx and distributed by
ARL Pathology under licence in Australia and New Zealand, Patent Pending.




Ovarian Cancer



ARL 114/1107



Ovarian Cancer Test Kit



HealthLinx Limited

HealthLinx ovarian cancer test packaging ready for Q3 product launch

Australian women will benefit first from simple high accuracy test

21 April 2008, Melbourne: Diagnostics company HealthLinx Limited (ASX:HTX) has finalised the packaging of its ovarian cancer test kit called OvPlex which will be distributed in Australia by ARL Pathology from the third quarter of 2008.

Product testing demonstrated that the OvPlex panel achieved a better than 93 percent ovarian cancer diagnostic efficiency.

The even more striking results were in assessing OvPlex for early stage ovarian cancer. The results were:

- Diagnostic efficiency 92.8 percent
- Sensitivity 89.2 percent
- Specificity 93.9 percent

The study was repeated in an independent laboratory and the results were reproducible.

Neither HealthLinx nor ARL Pathology is aware of any diagnostic in world markets that compares favourably against these results.

OvPlex is targeting a US\$260 million market per annum and HealthLinx is preparing for commissioning manufacturing.

“We are one step closer to full commercialisation with the packaging in place. We are on the verge of introducing OvPlex to the market,” said HealthLinx managing director, Mr Nick Gatsios

“This is important to our company and to the community. Ovarian cancer is an invasive cancer that is notoriously difficult to diagnose because the early stage symptoms are so vague. With this new cancer test women can receive more accurate diagnosis and receive treatment before the cancer spreads.”

HealthLinx specialises in ovarian cancer biomarkers and the development of multi-marker diagnostic tests using biomarkers. Biomarkers highlight particular compounds in blood and other body fluids that indicate disease or the effects of treatment.

Ovarian cancer develops without overt symptoms and usually by the time it has been diagnosed the cancer has spread beyond the ovaries and into the abdomen, bladder, bowel and omentum. Because there is no community-based screening test for ovarian cancer, over 75 percent of cases are diagnosed in the advanced stages and over 80 percent of these women will die within 5 years. If ovarian cancer is detected at an early stage and effectively treated, survival rate is more than 80 percent.

In the US about 23,000 women were diagnosed last year with about 14,000 deaths. The percentage is similar in Western Europe and Australia. In Australia, there were about 1,300 new cases of ovarian cancer diagnosed and over 900 deaths reported.

ABN 88 098 640 352

576 Swan Street Richmond VIC 3121

Telephone: +61 3 9208 4200 | Facsimile: +61 3 9208 4201

www.healthlinx.com.au

For personal use only

Enquires:

Nick Gatsios, HealthLinx Limited
Rudi Michelson (Monsoon Communications)

03 9208 4200
03 9620 3333

About HealthLinx Limited (ASX:HTX)

HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases. First commercial targets are:

- .. Ovarian cancer diagnostic (OvPlex) targeting US\$260m pa market
- .. Pregnancy diagnostic. This would be used in a woman's first prenatal visit to identify whether she is at high risk of pregnancy complications. Currently there is no product on the market for early stages of pregnancy.

A biomarker is a specific biochemical in the body that is used to measure progress of disease or the effects of treatment.

HealthLinx targets important markets with unmet needs. HealthLinx is developing product applications to successful Phase II biomarker trials and will then seek to out-license to partners for upfront and milestone payments and royalties on sales.

The company also has significant IP in Protein Depletion Technologies (ClearIT™) that depletes serum and other biological fluids of high abundant proteins. HealthLinx offers a fee for service to access the Cryptomics Platform that screens and identifies bio-active peptides for nutraceutical, functional foods and biological applications.

www.healthlinx.com.au

For personal use only